Noveris Health Sciences Inc., formerly Mydecine Innovations Group Inc., is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders such as nicotine addiction and posttraumatic stress disorder (PTSD). The Company focuses on the next generation of psychedelic medicine by creating innovative compounds with unmatched therapeutic potential through its clinical trial efforts with scientific and regulatory expertise.

Employees

Sector

Biotechnology & Medical Research

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Cap	4.39M 3.08M 2.75M 2.57M 2.33M 298M 4.42M 30.77M 12.02M 152M 11.56M 11.31M 487M	P/E 2024	-0.19x	P/E 2025	0.13x
Enterprise Value	13.96M 9.79M 8.75M 8.16M 7.41M 947M 14.07M 97.87M 38.24M 483M 36.77M 35.98M 1.55B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	99.95%	Yield 2024 *	-	Yield 2025	-

09-01	Noveris Health Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-21	Noveris Health Sciences to Raise C$500,000 From a Private Placement of Convertible Debentures	MT
08-19	Noveris Health Sciences Inc. announced that it expects to receive CAD 0.5 million in funding	CI
08-18	Noveris Health Sciences Receives Uspto Notice of Allowance for Aza-Substituted Psilocin Analogs and Signs Work Order with Api	CI
06-12	Noveris Health Sciences Appoints Nathan Mison as Chair of Advisory Board	CI
05-29	Noveris Health Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-30	Noveris Health Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-30	Noveris Health Sciences Inc. Auditor Raises 'Going Concern' Doubt	CI
04-28	Noveris Health Sciences Inc. signed a term sheet to acquire 49% stake in ELL Stem Cells for $1 million.	CI
03-17	Noveris Health Sciences Inc. announced that it has received CAD 2.310012 million in funding	CI
03-12	Noveris Health Sciences Inc. announced that it expects to receive CAD 2.5 million in funding	CI
03-10	Noveris Health Sciences Inc. Announces Board Changes	CI
03-10	Noveris Health Sciences Inc. Announces CEO Changes	CI

09-09	Noveris Health Sciences Announces Results of 2026 Annual General and Special Meeting	NE
08-20	Noveris Health Sciences Announces Proposed Private Placement of Convertible Debentures for up to $500,000	NE
08-18	Noveris Health Sciences Receives USPTO Notice of Allowance, and Signs Work Order with API	NE
08-06	Noveris Health Sciences Inc. Unaware of Any Material Change	NE
07-30	Noveris Health Sciences Joins BioAlberta	NE

Manager	Title	Age	Since
Jason Birmingham CEO	Chief Executive Officer	53	2026-03-09
John Ross DFI	Director of Finance/CFO	67	2022-09-15

Director	Title	Age	Since
Michael Callas BRD	Director/Board Member	-	2025-03-20
Peter Field BRD	Director/Board Member	-	2025-03-17
Jason Birmingham BRD	Director/Board Member	53	2026-03-09

New Age Farm Inc Stock Other OTC

Stocks

CA64157D1087

Biotechnology & Medical Research

Valuation: New Age Farm Inc

Latest news: New Age Farm Inc

Press Releases: New Age Farm Inc

Quotes and Performance

Managers and Directors: New Age Farm Inc

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEW AGE FARM INC	-4.17%	+28.73%	-	-	3.09M
WUXI APPTEC CO., LTD.	+4.16%	+4.16%	+49.37%	+94.17%	74.69B
ARGENX SE	+0.46%	-1.16%	+23.36%	+79.34%	58.81B
LONZA GROUP AG	+0.17%	-1.16%	+3.59%	+34.55%	48.45B
REVOLUTION MEDICINES, INC.	+0.50%	-1.77%	+331.24%	+702.20%	42.84B
IQVIA HOLDINGS INC.	-0.72%	-4.04%	+25.90%	+29.94%	42.79B
BEONE MEDICINES AG	+0.34%	-0.34%	+5.66%	+109.35%	41.25B
CELLTRION, INC.	-0.11%	+1.96%	+9.19%	+52.66%	31.13B
WUXI BIOLOGICS (CAYMAN) INC.	-2.07%	+1.16%	+35.00%	+26.28%	30.28B
BIONTECH SE	-0.50%	-3.37%	-9.42%	-14.35%	24.05B
Average	-0.20%	-0.25%	+52.65%	+123.79%	43.81B
Weighted average by Cap.	+0.69%	-0.54%	+55.51%	+130.20%

	2024	2025
Net sales	-	-
Net income	-3.15M -2.21M -1.97M -1.84M -1.67M -214M -3.18M -22.09M -8.63M -109M -8.3M -8.12M -349M	2.92M 2.05M 1.83M 1.71M 1.55M 198M 2.94M 20.47M 8M 101M 7.69M 7.53M 324M
Net Debt	6.87M 4.82M 4.31M 4.02M 3.65M 466M 6.93M 48.18M 18.82M 238M 18.1M 17.71M 762M	9.57M 6.71M 6M 5.59M 5.08M 650M 9.65M 67.09M 26.21M 331M 25.21M 24.66M 1.06B